


## Tin(IV) mesoporphyrin IX dichloride

<b>Cat. No.:</b>	HY-13707
<b>CAS No.:</b>	106344-20-1
<b>Molecular Formula:</b>	C <sub>34</sub> H <sub>36</sub> Cl <sub>2</sub> N <sub>4</sub> O <sub>4</sub> Sn
<b>Molecular Weight:</b>	754.29
<b>Target:</b>	Others
<b>Pathway:</b>	Others
<b>Storage:</b>	-20°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 5.56 mg/mL (7.37 mM; Need ultrasonic)					
	<b>Preparing Stock Solutions</b>	<b>Solvent</b>	<b>Mass</b>	<b>1 mg</b>	<b>5 mg</b>	<b>10 mg</b>
		<b>Concentration</b>				
		<b>1 mM</b>		1.3258 mL	6.6288 mL	13.2575 mL
		<b>5 mM</b>		0.2652 mL	1.3258 mL	2.6515 mL
<b>10 mM</b>		---	---	---		
Please refer to the solubility information to select the appropriate solvent.						
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 0.56 mg/mL (0.74 mM); Clear solution					

### BIOLOGICAL ACTIVITY

<b>Description</b>	Tin(IV) mesoporphyrin IX dichloride (Stanssoporfin) is a heme oxygenase (HO) inhibitor being developed for the prevention of hyperbilirubinemia in infants at risk of developing jaundice, extracted from patent WO2011103196A1 <sup>[1]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	HO <sup>[1]</sup>

### REFERENCES

[1]. Benjamin Levinson, et al. Treatment of infant hyperbilirubinemia using low dosages of stanssoporfin. US20080113955A1.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA